Corporate Fact Sheet - Valeant Pharmaceuticals

www.valeant.com
Investor Fact Sheet
EFFECTIVE APRIL 29, 2015
Symbol:
52 Week High:
VRX
$
52 Week Low:
214.75 $106.00
Close: As of
February 23, 2015
214.06
$
Market
Capitalization:
Shares
Outstanding:
72.96B 340.9M
$
Institutional
Ownership:
92%
Employees
Worldwide:
~17,000
Average Daily Volume
(52 weeks)
2.8M
shares
COMPANY OVERVIEW
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multi-national specialty pharmaceutical
company that develops and markets prescription and non-prescription pharmaceutical products that make
a meaningful difference in patients’ lives. Valeant is focused on dermatology, eye health and other niche
therapeutic areas targeting growth markets around the world.
Valeant is a diverse and decentralized organization committed to focusing on our key stakeholders while
delivering consistently high performance. Our values provide the overall direction for our company as well
as the tools necessary to rise to any challenge by leveraging our collective hard work and effort along with
an unwavering competitive spirit. These values help us set goals based on our organization’s potential and
our aspirations for it.
SENIOR MANAGEMENT
J. Michael Pearson
Chairman and Chief Executive Officer
Howard Schiller
Executive Vice President and Chief
Financial Officer
Robert Chai-Onn
Executive Vice President, General
Counsel and Corporate Secretary
Valeant’s strategy is to focus on the business of core geographies and therapeutic classes, manage pipeline
assets through strategic partnerships with other pharmaceutical companies and deploy cash with an
appropriate mix of selective acquisitions, share buybacks and debt repurchases. Our leveraged research and
development model is one key element to this business strategy and will allow us to advance development
programs to drive future commercial growth, while minimizing research and development expense.
Based in Laval, Quebec, Valeant employs approximately 17,000 people worldwide. For more information
about Valeant Pharmaceuticals International, please visit our corporate website at www.valeant.com.
VALEANT LATE-STAGE R&D PORTFOLIO
Dr. Ari Kellen
Executive Vice President and
Company Chairman
PRODUCT
CATEGORY
DESCRIPTION
EXPECTED
LAUNCH YEAR
EnVista® Toric
Eye Health
Toric IOL
2016
Laizer D. Kornwasser
Executive Vice President and Company
Group Chairman
Luminesse™
(Brimonidine)
Eye Health
Eye-whitening OTC
2016
Vesneo™
Eye Health
Glaucoma
2016
Lotemax® Gel
Next Gen
Eye Health
Post-operative pain and inflammation
2016
Ultra® Plus Powers
Eye Health
Contact lens
2016
BioTrue® Toric
Eye Health
Contact lens
2016
Arestin® LCM
Oral Health
Antibiotic treatment for periodontal (gum) disease
2016
Emerade®
Allergy
Anaphylaxis
2016/2017
IDP-118
Dermatology
Moderate to severe plaque psoriasis
2017/2018
IDP-120
Dermatology
Novel acne combination
2019
Pavel Mirovsky
Executive Vice President and President
& General Manager EMEA
Brian Stolz
Executive Vice President of
Administration and Chief Human
Capital Officer
INVESTOR RELATIONS
Laurie W. Little
Sr. Vice President
Investor Relations
(949) 461-6002
E-mail: ir@valeant.com
REVENUE
CASH EPS
8B
$8.26 B
8.0
7B
7.0
6B
6.0
$5.76 B
5B
$8.34
$6.24
4.0
3B
$4.51
•Valeant expands Bausch + Lomb
manufacturing facility, adding 120
new jobs in Rochester, N.Y.
$2.93
2.0
$2.46 B
1B
•FDA approves Onexton™ Gel for
the treatment of acne vulgaris
3.0
$3.55 B
2B
•Valeant completes its acquisition
of substantially all the assets of
Dendreon Corporation.
5.0
4B
$2.05
•Sale of fillers and toxin assets to
Galderma completed
1.0
$1.18 B
500 M
0
2010
2011
2012
2013
2014
* A s a result of the Biovail’s merger with Valeant, revenue reflects Biovial standalone
operations as they existed prior to the completion of the merger and combined
Valeant’s results only for the period subsequent to the completion of the merger on
September 28, 2010.
2010
HIGHLIGHTS
•Valeant completes its acquisition
of Salix Pharmaceuticals.
2011
2012
2013
2014
*A s a result of the Biovail’s merger with Valeant, Cash EPS reflects Biovial standalone
operations as they existed prior to the completion of the merger and combined
Valeant’s results only for the period subsequent to the completion of the merger on
September 28, 2010.
•Valeant completes acquisition of
PreCision Dermatology
•FDA approves Jublia for treatment
of onychomycosis
RECENT VALEANT ACQUISITIONS
Bausch + Lomb
In August 2013, Valeant completed its acquisition of Bausch + Lomb. The integration of Valeant’s eye care businesses into Bausch
+ Lomb’s operations offers a vast product portfolio and a full array of innovative products in the development pipeline focused on
protecting, enhancing and restoring people’s eyesight. The acquisition has also served to establish Valeant’s presence in such
emerging markets as China, among others.
Solta Medical, Inc.
On January 23, 2014, Valeant completed its acquisition of Solta Medical. Solta designs, develops, manufactures and markets
energy-based medical device systems for aesthetic applications.
PreCision Dermatology, Inc.
On July 8, 2014, Valeant completed its acquisition of PreCision Dermatology, Inc., which develops and markets high-quality
dermatology products treating a number of topical disease states such as acne and atopic dermatitis.
Dendreon Corporation
On February 23, 2015, Valeant completed its acquisition of substantially all of the assets of Dendreon Corporation, following approval
from the Bankruptcy Court. These assets include the worldwide rights to PROVENGE® (sipuleucel-T), an immunotherapy treatment
designed to treat advanced prostate cancer.
Salix Pharmaceuticals
On April 1, 2015, Valeant completed its acquisition of Salix Pharmaceuticals Ltd., a specialty pharmaceutical company that offers
innovative gastrointestinal treatments.
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. ORGANIC GROWTH - BY SEGMENT
FOR THE THREE MONTHS ENDED MARCH 31, 2015 (in millions)
PRODUCT SALES
QTD REVENUES
SAME STORE(C)
PRO FORMA(C)
Total U.S.(a)
$1382.4
26%
36%
ROW Developed (b)
$348.8
-1%
-1%
Developed Markets
$1,731.1
18%
25%
Emerging Markets
$416.4
7%
7%
$2147.5
15%
21%
TOTAL PRODUCT SALES
(a) Includes Valeant’s attributable portion of revenue from joint ventures (JV) - $0.6M Q1’15 and $0.7M Q1’14.
(b) Includes Valeant’s attributable portion of revenue from joint ventures (JV) - $3.1M Q1’14.
(c)Organic Growth Definitions: Same Store (SS): This measure provides growth rates for businesses that have been owned for one year or more. ((Current Year Total product sales – acquisitions within the last
year + YoY FX impact)- (Prior Year Total product sales – divestitures & discontinuations))/( Prior Year Total product sales – divestitures & discontinuations). Pro Forma (PF): This measure provides year over
year growth rates for the entire business, including those that have been acquired within the last year.